Tarzana Treatment Centers, Inc.
Welcome,         Profile    Billing    Logout  
 9 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Oliveto, Alison
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
07/26
12/26
Mooney, Larissa J
RXR, NCT06023459: Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings

Not yet recruiting
3
144
US
Injectable extended-release buprenorphine, XR-BUP (Brixadi), Sublingual buprenorphine-naloxone, SL-BUP
Yih-Ing Hser, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), The Emmes Company, LLC, University of California, Los Angeles, RAND, Cornell University, Oregon Health and Science University, University of Illinois at Chicago, University of Washington, West Virginia University
Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
11/24
12/24
SICA 2, NCT05322941: Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)

Completed
2
333
US
AEF0117, 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one, Placebo oral capsule, Placebo
Aelis Farma, National Institute on Drug Abuse (NIDA)
Marijuana Abuse
04/24
07/24
Hser, Yih-Ing
RXR, NCT06023459: Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings

Not yet recruiting
3
144
US
Injectable extended-release buprenorphine, XR-BUP (Brixadi), Sublingual buprenorphine-naloxone, SL-BUP
Yih-Ing Hser, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), The Emmes Company, LLC, University of California, Los Angeles, RAND, Cornell University, Oregon Health and Science University, University of Illinois at Chicago, University of Washington, West Virginia University
Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
11/24
12/24
Bachrach, Kenneth M
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
07/26
12/26
Rakhmanov, Tolib M
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
07/26
12/26

Download Options